Peripheral neuropathies II: Clinical syndromes

Published on 09/04/2015 by admin

Filed under Neurology

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1100 times

Peripheral neuropathies II

Clinical syndromes

Demyelinating neuropathies

Guillain–Barré syndrome

Guillain–Barré syndrome (GBS) is a monophasic, predominantly motor polyradiculopathy. It develops over days to 4 weeks and can affect limbs and cranial nerves. It can vary in severity from mild weakness to complete paralysis requiring ventilatory support in 10–20% of patients. There are mild sensory symptoms and signs. At onset, reflexes may be present with significant weakness but then soon disappear. The autonomic nervous system is variably affected, producing cardiac arrhythmias and hypo- or hypertension. Recovery begins spontaneously after a few weeks.

GBS affects all ages and occurs in 2 per 100 000 per year. About 70% of patients have a history of antecedent infection: best established are Campylobacter jejuni, cytomegalovirus and Epstein–Barr virus.

Diagnosis is primarily clinical with support from neurophysiological studies and a finding of acellular CSF with raised protein. There are some patients whose neurophysiological findings indicate an axonal degeneration, the ‘acute axonal’ form of GBS, which more commonly follows Campylobacter infection.

Management consists of support and specific measures to shorten the illness. It is essential to monitor patients closely with regular measurements of vital capacity (VC) and looking for evidence of autonomic dysfunction. Patients with a VC below 1 litre require ventilation. Close attention to pressure areas, prophylaxis against venous thrombosis, and chest and limb physiotherapy are important in these vulnerable patients. Neuralgic pain can be treated with pain-modulating agents. Communication aids will be needed in paralysed patients. Helping the patient to understand their predicament and providing psychological support is important.

Two treatments have been found to shorten the course of disease. Plasma exchange and intravenous immunoglobulin will both shorten the illness to a similar degree. Both are more effective the sooner they are given (<2 weeks). They should be given to patients who cannot walk and are chair- or bed-bound.

The mortality rate is about 5%. Twenty per cent of patients have a continuing motor deficit at 1 year and 3% have a recurrence. The axonal form has a slower and less complete recovery.

The Miller Fisher variant is a rare association of areflexia, ophthalmoplegia and ataxia, and is associated with a specific antiganglioside antibody GQ1b.

Axonal neuropathies

Diabetic neuropathies

Diabetes mellitus is the most common cause of neuropathies in the western world. About 15% of patients with diabetes have symptomatic neuropathies, the proportion increasing with duration of disease. Subclinical abnormalities in neurophysiological studies are almost universal after 10 years of diabetes. There are several patterns of peripheral neuropathy in diabetes.

Other systemic diseases

Distal symmetrical axonal neuropathies are seen in a range of other systemic illnesses (Table 1), including hypothyroidism, uraemia, rheumatoid arthritis and systemic lupus erythematosus. The connective tissue diseases can also cause vasculitic neuropathies.

Table 1 Types of peripheral neuropathy

Systemic Metabolic Diabetes, etc.
Toxic Neurotoxins, ethyl alcohol, etc.
Nutritional Vitamin B12
Extrinsic Entrapment mononeuropathies  
Intrinsic Metabolic Refsum’s disease, etc.
Immunological Demyelinating: Guillain–Barré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy
  Vasculitis
Neoplastic Monoclonal band
Degenerative Axonal neuropathies
Infectious Leprosy
Genetic Hereditary motor and sensory neuropathy, etc.

Nutritional deficiencies

Patients with nutritional deficiencies (Box 1, p. 103) often have more than one vitamin deficiency. This can be associated with other problems such as alcoholism, in which the major factor is nutritional deficiency. The clinical presentation is of a painful, predominantly sensory distal symmetrical axonal neuropathy. Treatment is with appropriate vitamins. Vitamin B12 deficiency is more complicated because there is often an associated myelopathy (subacute combined degeneration of the cord). In the full syndrome, there is a progressive paraparesis, with loss of proprioception, prominent distal paraesthesiae and associated dementia. Vitamin B12 measurement and the demonstration of antiparietal cell antibodies and malabsorption of vitamin B12 give a diagnosis.

Vasculitic neuropathies

These usually occur in the setting of systemic vasculitic disease such as Wegener’s granulomatosis, polyarteritis nodosa, rheumatoid arthritis or Sjögren’s syndrome. The diagnosis is made histologically with serological support. Treatment is of the underlying disorder. The previously poor prognosis has improved with the aggressive immunosuppressive regimens now used. Rarely, vasculitis can be restricted to the peripheral nerve, so-called non-systemic vasculitis. This has a better prognosis.

Share this: